This article reports the results of a post hoc analysis of the multicenter, randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) study, which aimed to investigate the effects of dutasteride (0.5 mg), tamsulosin (0.4 mg), and their combination on storage and voiding symptoms in 4844 men aged X50 years with moderate-to-severe lower urinary tract symptoms (International Prostate Symptom Score X12), prostate volume (PV) X30 cm 3 and PSA 1.5-10 ng ml
Introduction
Lower urinary tract symptoms (LUTSs) in men can be classified as voiding symptoms (those associated with passage of urine) or storage symptoms (those associated with storage of urine in the bladder), 1 with storage symptoms being the more common. 2 Typical voiding symptoms of reduced stream, intermittency, hesitancy, straining and incomplete emptying are caused by obstruction of the urethra, often arising from benign prostatic enlargement (BPE), usually secondary to BPH. 3, 4 Typical storage symptoms of frequency, nocturia, urgency and urinary incontinence are thought to arise from altered smooth muscle function in the prostate and bladder, and are common in both BPE and overactive bladder syndrome. The prevalence of LUTS increases as men age. For example, in the largest population-based study of LUTS to date, which combined data from five countries, both voiding and storage symptoms were less prevalent in younger men (19.9 and 37.5% at age p39 years, respectively) and increased with age (to 24.1 and 50.6% at age 40-59 years and 37.2 and 73.9% at age X60 years, respectively). 2 This also shows that storage symptoms are more common than voiding symptoms at all ages examined. Interestingly, in this study only 10% of men aged 40-59 experienced both voiding and storage symptoms, whereas 22% of men aged X60 experienced both.
The preferred management strategies for LUTS related to overactive bladder syndrome or to BPE seem logical based on underlying pathophysiology. In overactive bladder syndrome, symptoms are treated with antimuscarinics, which block M 2 and M 3 receptors in the bladder detrusor muscle, regardless of whether detrusor overactivity is caused by bladder outlet obstruction (BOO) secondary to BPE. 5 Symptoms of BPE can be relieved with a-blockers, which inhibit a 1 -adrenoceptors in the bladder neck and prostate smooth muscle, although a 1 -adrenoceptors in the detrusor muscle may also be important. [6] [7] [8] [9] In patients with moderate-to-severe LUTS and prostate enlargement, 5a reductase inhibitors (5ARIs) are recommended; by reducing prostate volume (PV), they decrease urethral obstruction, provide continuous symptom improvements and reduce the rate of progression to acute urinary retention (AUR) and surgery. [10] [11] [12] Although a-blockers are effective for short-term improvements in both the storage and voiding components of LUTS, many men do not respond to treatment. For example, in one study, between 30 and 60% of men treated with different doses of terazosin showed o30% improvement in total symptom score, 13 whereas in the Combination of Avodart and Tamsulosin (CombAT) study 45% of men treated with tamsulosin experienced o25% improvement in symptoms after 2 years of treatment. 14 As 5ARIs are known to reduce voiding symptoms in men with BPH, 12 the use of combinations of these two classes of compound has been examined, and combined treatment with an a-blocker and a 5ARI has been shown to provide superior improvement in LUTS due to BPE than either monotherapy. 14, 15 Two-year results from the CombAT study showed that a combination treatment with the 5ARI dutasteride and the a-blocker tamsulosin is more effective than either monotherapy for improving the symptoms, peak flow rate and quality of life in men with moderate-to-severe LUTS and prostatic enlargement. 14, 16 As expected, dutasteride (but not tamsulosin) reduced PV, and tamsulosin provided faster symptom relief than dutasteride. However, there was no difference in symptom relief between the two agents by almost 1 year, and the symptom improvement with dutasteride exceeded that with tamsulosin after 1 year in men with larger prostates. 17 With this post hoc analysis, we aimed to examine more closely the nature of symptom improvements with these two agents and their combination. As storage symptoms are more common than voiding symptoms, 2, 18 and are generally considered more bothersome to patients, 18 and as BPE is a progressive disorder that can result in AUR and the need for surgery, a treatment approach that targets the underlying disease mechanism and has the potential to improve storage symptoms would be advantageous.
This paper reports on a post hoc analysis of the planned 2-year results from the CombAT study, and explores the effects of dutasteride, tamsulosin, and their combination on storage and voiding symptoms in men with moderate-to-severe LUTS and enlarged prostate, as measured by subscores of the International Prostate Symptom Score (IPSS). We report results for the group as a whole, and stratified by baseline PV.
Materials and methods

Study design and assessments
The design and conduct of the CombAT study have been reported earlier. 14, 16 Eligible men were aged X50 years, with BPH, IPSS X12 points, PV X30 cm 3 , total serum PSA 1.5-10 ng ml À1 and Q max 5-15 ml s À1 , and a minimum voided volume of X125 ml. 14 The principal exclusion criteria were history or evidence of prostate cancer, earlier prostatic surgery or a history of AUR within 3 months before study entry. 14 After enrollment, patients received placebo tamsulosin or placebo dutasteride during a 4-week single-blind runin period, followed by 4 years of double-blind once-daily treatment with 0.5 mg dutasteride plus 0.4 mg tamsulosin, 0.5 mg dutasteride plus placebo tamsulosin or 0.4 mg tamsulosin plus placebo dutasteride. 16 Patients administered the study drugs themselves and returned to the clinic for assessment at 3-month intervals. 16 Analyses of primary and secondary end points were planned at 2 and 4 years; the primary efficacy end point at 2 years was the change in IPSS from baseline. 16 The IPSS consists of eight questions, seven of which relate to symptoms ( Table 1 ) and one to health-related quality of life. 19 The seven symptom questions are each scored on a scale of 0 (least severe) to 5 (most severe). For the present analyses, subscores were calculated for questions relating to storage (questions 2, 4 and 7) and voiding (questions 1, 3, 5 and 6) symptoms.
Statistical analyses
Analyses included the intention-to-treat population (all patients randomized to double-blind study treatment after the 4-week placebo run-in period). 16 In a post hoc analysis, the mean change from baseline IPSS storage and voiding subscores was summarized by treatment group using the last observation carried forward approach. 16 The change from baseline IPSS (storage or voiding) was determined at each post-baseline assessment using a general linear model with adjustments for treatment, investigative site cluster and baseline IPSS (storage or voiding). Pairwise treatment comparisons from the general linear model were carried out at a ¼ 0.05. These analyses were conducted outside of the Combination therapy and BPH storage and voiding symptoms E Becher et al protocol-specified primary and secondary endpoint hierarchy, and no formal adjustments were made for multiplicity of tests. Data are presented as mean ± s.e., unless otherwise stated.
Results
Baseline characteristics and disposition
The baseline characteristics and disposition of the patients enrolled in the CombAT study have been described earlier.
14 A total of 4844 men were randomized to treatment, of whom 3822 (79%) completed the month 24 visit; rates of discontinuation were similar across the three treatment groups.
14 Baseline characteristics were similar between the treatment groups; patients were predominantly Caucasian (88%), had a mean age of 66.1 years, mean PV of 55.0 cm 3 and mean serum PSA of 4.0 ng ml À1 . The mean total IPSS score was 16.4 ± 0.09 at baseline. 14 The mean IPSS storage subscore at baseline was 7.3 ± 0.08 in the combination group, 7.2 ± 0.07 in the dutasteride monotherapy group and 7.2±0.07 in the tamsulosin monotherapy group. The mean IPSS voiding subscores at baseline were 9.3±0.11, 9.2±0.11 and 9.2 ± 0.11 in the combination, dutasteride and tamsulosin groups, respectively.
International Prostate Symptom Score storage subscores
At month 24, the mean reduction in storage subscore from baseline was significantly greater in the combination group (À2.2 ± 0.07) than in the dutasteride (À1.7 ± 0.07; Po0.001) and the tamsulosin monotherapy groups (À1.6 ± 0.07; Po0.001) ( Figure 1 and 2) ; for each individual storage question of the IPSS (questions 2, 4 and 7), the reduction in score was significantly greater with combination therapy than with either monotherapy (Po0.001). Mean storage subscores were reduced from baseline to 4.9 ± 0.07 in the combination group, 5.4 ± 0.08 in the dutasteride monotherapy group and 5.5±0.08 in the tamsulosin monotherapy group.
The mean reduction in storage subscore was significantly greater in the combination group than in the dutasteride monotherapy group from month 3, and than in the tamsulosin group from month 12 ( Figure 2 ). Dutasteride and tamsulosin monotherapies reduced the storage subscore to a similar extent at month 24 (À1.7±0.07 vs À1.6±0.07, respectively; P ¼ 0.30) (Figure 2) , and although tamsulosin achieved significantly greater mean reductions from baseline than dutasteride monotherapy at months 3, 6 and 9, the difference between the two monotherapy groups had disappeared by month 12 (Figure 2 ).
International Prostate Symptom Score voiding subscores
At month 24, the mean reduction in IPSS voiding subscore from baseline was significantly greater in the combination group (À4.0±0.10) than in the dutasteride (À3.2 ± 0.10; Po0.001) and the tamsulosin monotherapy groups (À2.7±0.10; Po0.001), and significantly greater with dutasteride than with tamsulosin monotherapy (Po0.001, Figures 1 and 3) . For each individual voiding question of the IPSS (questions 1, 3, 5 and 6), the reduction in score was significantly greater with combination therapy than with either monotherapy (P p0.001). These reductions resulted in subscores of 5.2±0.10 in the combination group, 5.9 ± 0.11 in the dutasteride monotherapy group and 6.4±0.11 in the tamsulosin monotherapy group, respectively.
The mean reduction in voiding subscores was significantly greater in the combination group than in the dutasteride group from month 3 and the tamsulosin group from month 6 ( Figure 3 ). Tamsulosin reductions in voiding subscores were greater than dutasteride at months 3, 6 and 9, but the difference was no longer significant by month 12. From month 18 onward, the reduction in voiding subscore was significantly greater with dutasteride than with tamsulosin ( Figure 3 ).
International Prostate Symptom Score storage and voiding subscores by baseline prostate volume
When evaluating the change in IPSS symptoms from baseline, a significant treatment by baseline PV interaction was noted at month 24 for both the IPSS storage Combination therapy and BPH storage and voiding symptoms E Becher et al (P ¼ 0.01) and IPSS voiding (Po0.001) subscores. Therefore, treatment effects were determined in baseline PV tertiles.
In men with baseline PV in the lower two tertiles (30 to o42 and 42 to o58 cm 3 ), reduction in storage subscores was significantly greater with the combination than with dutasteride or tamsulosin monotherapy at month 24 ( Figure 4a ). In men with baseline PV in the highest tertile (X58 cm 3 ), at month 24 the reduction in storage subscores was significantly greater with both the combination and dutasteride monotherapy, compared with tamsulosin monotherapy.
In men with baseline PV in the lowest tertile, reduction in voiding subscores was significantly greater with the combination than with dutasteride or tamsulosin monotherapy at month 24 ( Figure 4b) . In both the middle and upper tertiles (that is, baseline PV X42 cm 3 ), the reduction in voiding subscores at 24 months was significantly greater with both combination treatment and dutasteride monotherapy than with tamsulosin monotherapy.
Discussion
After 2 years of treatment, the combination of dutasteride and tamsulosin resulted in significantly greater reductions in both storage and voiding subscores, and each individual storage and voiding question, compared with each monotherapy. This was maintained in all prostate sizes studied. In addition, dutasteride achieved significantly greater reduction than tamsulosin in the voiding subscore (incomplete emptying, hesitancy, weak stream and straining). This was true in the group as a whole and also in the upper two tertiles of PV (X42 cm 3 ). In men with the largest prostates (X58 cm 3 ), dutasteride also achieved significantly greater reductions, not only in voiding symptoms but also in the storage symptom subscore (frequency, urinary incontinence and nocturia).
The findings we report here are in line with the main findings of the CombAT study and also with expectations based on the drugs' differing but complementary modes of action. 14 We show that a-blocker monotherapy rapidly improves storage and voiding symptoms (although improvement in voiding symptoms is not sustained), that 5ARI monotherapy improves voiding symptoms (and, interestingly, also storage symptoms) more gradually, but with sustained effect, and that combination therapy achieves rapid and sustained improvement of both storage and voiding symptoms (Figures 2 and 3) . 14 For example, we found that combination therapy achieved greater relief of storage symptoms than dutasteride from month 3 and than tamsulosin from month 12. For voiding symptoms, combination therapy was superior to dutasteride from month 3 and to tamsulosin from month 6; dutasteride matched tamsulosin by month 12 and achieved superior relief of voiding symptoms from month 18. Although this is a post hoc analysis, the highly statistically significant effects-in line with the primary endpoint findings of the CombAT study-and the consistency between effects on each subscore and each individual question of that subscore lend support to the validity of the results.
Few other trials of combination treatment have reported effects on storage and voiding subscales of the IPSS. In an analysis of data from the Veteran's Affairs trial of finasteride, terazosin, their combination and placebo, Barry et al. 20 reported that although symptoms do indeed cluster into separate storage and voiding domains, this separation is not clinically useful. They found that the storage and voiding subscales responded equally in each particular treatment group. This conclusion is limited by the fact that this study did not detect Combination therapy and BPH storage and voiding symptoms E Becher et al any significant effect of the 5ARI finasteride on symptoms, compared with placebo, by 1 year. This may be due to the small average prostate size of men included or the short duration of the trial. Roehrborn et al. 21 have assessed the utility of voiding and filling (storage) subscores in predicting BPH progression in the PROSCAR Long-Term Efficacy and Safety Study (PLESS) study. They noted that baseline overall symptom severity is a poor predictor of AUR and that the voiding subscore, PV and PSA were significant predictors of spontaneous AUR. However, because the study only contained placebo and a 5ARI, no determination can be made with regard to response to therapy with respect to various pharmacological classes of BPH treatment.
In Medical Therapy of Prostatic Symptoms( MTOPS), at the end-of-study evaluation (4 years), improvement in the overall American Urological Association (AUA) symptom score was significantly greater with combination therapy than with finasteride (Po0.001) or doxazosin (P ¼ 0.006), and with doxazosin than with finasteride (P ¼ 0.001). However, the effect of each treatment on separate storage and voiding symptoms has not been reported.
Several aspects of our results seem surprising. First, dutasteride monotherapy matched tamsulosin's improvement in storage symptoms: by 15 months both agents achieved a 1.8-point improvement in storage subscores. This improvement in storage symptoms by a 5ARI is in line with Mirone's suggestion that storage symptoms arise from maladaptive changes in bladder structure and function, which are driven by BOO. 22 Therefore, the progressive reduction of PV known to occur with 5ARI treatment may result in alleviation of BOO. 23 We hypothesize that it is the alleviation of the mechanical stress caused by BOO that then allows reversal of structural and functional changes in the bladder, thus leading to improvements in storage symptoms with a 5ARI of comparable magnitude to an a-blocker after 15 months of therapy.
Second, the improvement of voiding symptoms caused by tamsulosin monotherapy reached a plateau at just under 3 points, compared with a 4-point improvement with combination therapy. This suggests that a-blockers may reach their mechanical limits to effectively reduce muscle tone and overcome the voiding symptoms in men with large prostates. Indeed, as shown in Figure 4b , the magnitude of effect of tamsulosin on voiding symptoms decreased as PV increased. It is also possible that a 1A receptors in the bladder neck and central nervous system, or preganglionic a 1A receptors, are involved in sympathetic facilitation of storage and voiding reflexes. 24, 25 It would be interesting to explore treatment effects on individual LUTS using a more appropriate instrument, such as the International Consultation on Incontinence Questionnaire Male Lower Urinary Tract Symptoms, which includes separate scores for voiding (on a scale of 0-20) and urinary incontinence (on a scale of 0-24). When considering our results in a wider clinical context, it is interesting to note that the type of LUTS experienced by men does not always correlate with actual pathophysiological changes. For example, Hyman et al. 26 showed that detrusor instability, measured in 160 men, only correlated with urge incontinence (and no other IPSS storage symptoms). In addition, 68% of the men they evaluated had measurable BOO, regardless of the main complaint. Hence, is BOO the predominant pathology underlying LUTS? This agrees with Mirone's view that BOO is the primary driver of pathophysiological changes in the bladder that lead to LUTS, and implies that treatment regimens that can treat the underlying causes of BOO, such as 5ARIs reducing PV in BPH, should be favored. This would not only reduce the rate of progression to AUR and surgery but also provide symptom relief. However, the relationship between outlet obstruction and improvement of storage symptoms is not straightforward. Malloy et al. 9 note that relief of obstruction does not necessarily improve storage symptoms (for example, after surgical resection), and improvement in storage symptoms with drug treatment often occurs more rapidly than could be accounted for by resolution of detrusor hypertrophy. They suggest that ablocker action at a 1A and a 1D adrenoceptors in the detrusor muscle underlies rapid relief of storage symptoms, rather than actions at the bladder neck and prostate smooth muscle to reduce obstruction. 9 Our results support this concept: an a-blocker provides rapid improvement in storage symptoms, and over time a 5ARI improves storage symptoms, possibly secondary to improvement of voiding symptoms, relief of obstruction and effects on detrusor hypertrophy. The superior improvement in storage symptoms with combination treatment, compared with each monotherapy, supports the suggestion that the monotherapies are acting through various mechanisms.
Conclusions
Our analyses confirm that combination therapy provides better control of both voiding and storage symptoms, compared with each monotherapy, irrespective of PV (for men with PV X30 cm 3 ). Our results provide the first data to show that, compared with an a-blocker, a 5ARI may result in greater long-term control of not only overall urinary symptoms but also specific aspects of LUTS in men with prostate enlargement. The 5ARI dutasteride is as effective as the a-blocker tamsulosin for control of storage symptoms and provides greater relief from voiding symptoms by 24 months of treatment. This shows that reduction in PV and relief of obstruction with 5ARIs (alone, or in combination with an a-blocker) over time not only improves voiding symptoms but also leads to improvement in bladder-related storage symptoms. This supports the use of these agents, alone or in combination with an a-blocker, in men with LUTS associated with BPE.
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